Peter Ledwon
Impact in
- Reproductive Medicine top 5%
- Ovarian cancer diagnosis and treatment
- Cancer Research top 10%
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
Papers in
-
- Ovarian cancer diagnosis and treatment 5
- Hypothalamic control of reproductive hormones 2
-
- Endometrial and Cervical Cancer Treatments 2
- Co-authors
- Jalid Sehouli (6 shared papers)Werner Lichtenegger (5 shared papers)Oumar Camara (2 shared papers)Dirk Elling (2 shared papers)Peter Klare (3 shared papers)Dirk Stengel (3 shared papers)G. Heinrich (1 shared paper)Jens‐Uwe Blohmer (1 shared paper)
- Journals
- Cancer Chemotherapy and Pharmacology (2 papers)Annals of Oncology (2 papers)Journal of Endocrinology (1 paper)Experimental and Clinical Endocrinology & Diabetes (1 paper)The Lancet Oncology (1 paper)
- Partner nations
- Germany
In The Last Decade
Peter Ledwon
13 papers receiving 549 citations
Peter Ledwon's Hit Papers
Peers
Comparison fields: 5 of 41
- Reproductive Medicine 140
- Cancer Research 150
- Oncology 117
- Genetics 91
- Obstetrics and Gynecology 22
Countries citing papers authored by Peter Ledwon
This map shows the geographic impact of Peter Ledwon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Ledwon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Ledwon more than expected).
Fields of papers citing papers by Peter Ledwon
This network shows the impact of papers produced by Peter Ledwon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Ledwon. The network helps show where Peter Ledwon may publish in the future.
Co-authors
The 25 scholars most cited alongside Peter Ledwon, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer Hit paper breakdown → | 2022 | 329 |
| 2 | 2020 | 131 | |
| 3 | 2002 | 29 | |
| 4 | 2007 | 29 | |
| 5 | 2013 | 15 | |
| 6 | 2017 | 12 | |
| 7 | 2013 | 7 | |
| 8 | 2018 | 5 | |
| 9 | 2022 | 5 | |
| 10 | 1990 | 2 | |
| 11 | 2001 | 1 | |
| 12 | 2009 | 1 | |
| 13 | 2012 | 1 |
About Peter Ledwon
Peter Ledwon is a scholar working on Reproductive Medicine, Obstetrics and Gynecology, Oncology, Health Information Management and Management Information Systems, having authored 13 papers that have together received 567 indexed citations. Recurring topics across this work include Ovarian cancer diagnosis and treatment (5 papers), Hypothalamic control of reproductive hormones (2 papers), Endometrial and Cervical Cancer Treatments (2 papers), Global Cancer Incidence and Screening (1 paper), Clinical practice guidelines implementation (1 paper), Autopsy Techniques and Outcomes (1 paper), PARP inhibition in cancer therapy (1 paper) and Healthcare Quality and Management (1 paper). The work is most often cited by research in Reproductive Medicine (140 citations), Cancer Research (150 citations), Oncology (117 citations), Genetics (91 citations) and Obstetrics and Gynecology (22 citations). Peter Ledwon has collaborated with scholars based in Germany. Frequent co-authors include Jalid Sehouli, Werner Lichtenegger, Oumar Camara, Dirk Elling, Peter Klare, Dirk Stengel, G. Heinrich, Jens‐Uwe Blohmer, Marek Zygmunt and Antje Kristina Belau. Their work appears in journals such as Cancer Chemotherapy and Pharmacology, Annals of Oncology, Journal of Endocrinology, Experimental and Clinical Endocrinology & Diabetes and The Lancet Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.